Clinical Symptoms of Sjögren's Syndrome and Systemic Lupus Erythematosus
Both Sjögren's syndrome and systemic lupus erythematosus share overlapping symptoms including arthralgia, myalgia, fatigue, and sicca features, but each has distinct hallmark manifestations that guide diagnosis and impact prognidity. 1
Sjögren's Syndrome: Core Clinical Features
Primary Glandular Manifestations
Sjögren's syndrome is fundamentally defined by dry eye and dry mouth associated with systemic immune dysfunction, resulting from lymphocytic infiltration of lacrimal and salivary glands 1. The key symptoms include:
- Xerostomia (dry mouth): Present in approximately 85% of patients
- Xerophthalmia (dry eyes): Affects about 76% of patients
- Parotid gland swelling: Episodic or persistent enlargement
- Dental complications: Increased caries, difficulty swallowing dry foods
Systemic Manifestations Beyond Sicca
The disease extends well beyond dryness 1, 2:
- Musculoskeletal: Arthralgia and myalgia (non-erosive arthritis pattern)
- Constitutional: Profound fatigue (often the most debilitating symptom)
- Pulmonary: Interstitial lung disease in 12% of cases
- Renal: Renal tubular acidosis (22% of patients)
- Cutaneous: Xerosis cutis, pruritus, leukocytoclastic vasculitis, subacute cutaneous lupus-like lesions 3
- Neurological: Peripheral neuropathy
Critical Prognostic Concerns
Diagnosis and treatment of underlying systemic immune disorders may decrease morbidity and may even be lifesaving 1. Patients face increased risk for:
- Lymphoproliferative disorders: Patients with decreased C4 levels at diagnosis have higher lymphoma risk
- Vasculitic complications: Potentially life-threatening
- Ocular complications: Scleritis, sterile keratitis, uveitis
Associated Autoimmune Features
- Thyroid dysfunction or autoimmune thyroiditis (primary Sjögren's)
- Can occur with rheumatoid arthritis, scleroderma, or SLE (secondary Sjögren's) 1
Systemic Lupus Erythematosus: Core Clinical Features
Characteristic Manifestations
SLE presents with highly variable clinical features characterized by remissions and flares 4:
Mucocutaneous (most visible):
- Facial rash: Present in 46% of SLE-only patients (malar or discoid patterns)
- Photosensitivity
- Oral ulcers
- Alopecia
Musculoskeletal:
- Arthritis (typically non-erosive, symmetric polyarthritis)
- Arthralgia
- Myalgia
Renal (major prognostic determinant):
- Proteinuria and nephrotic syndrome: Occurs in 31% of SLE patients
- Glomerulonephritis (various classes)
- Progressive renal dysfunction
Cardiopulmonary:
- Serositis: Pleuritis and pericarditis (highly characteristic)
- Pulmonary involvement
Neuropsychiatric (severe manifestations):
- Seizures and psychosis: Critical diagnostic features
- Acute confusional states
- Cranial or peripheral neuropathy
- Cognitive dysfunction
Hematologic:
- Anemia
- Thrombocytopenia
- Leukopenia
Life-Threatening Complications
SLE patients are at increased risk for co-morbidities that significantly impact mortality 4:
- Infections: Urinary tract and systemic infections (leading cause of death)
- Cardiovascular disease: Accelerated atherosclerosis, hypertension
- Thromboembolic events: Especially with antiphospholipid antibodies
- End-stage renal disease
- Malignancies: Particularly non-Hodgkin's lymphoma
Overlap Syndrome: SLE-Sjögren's (SLE-SS)
Distinguishing Features of Combined Disease
When both conditions coexist (occurring in approximately 11-18% of SLE patients), the clinical picture shows distinct characteristics 5, 6, 7, 8:
More common in SLE-SS compared to SLE alone:
- Sicca symptoms (xerostomia 85%, xerophthalmia 76%)
- Oral ulcers (more frequent)
- Arthritis/arthralgia
- Pulmonary involvement (interstitial lung disease)
- Peripheral neuropathy
- Older age at onset (mean 43 years vs 32 years)
Less common in SLE-SS compared to SLE alone:
- Renal involvement: Nephrotic syndrome only 7% vs 31% in SLE-only 7
- Central nervous system involvement: 5% vs 20%
- Facial rash: 10% vs 46%
Laboratory distinctions:
- Higher anti-SSA/Ro (83% vs 43%) and anti-SSB/La (39% vs 8%) antibodies
- Higher rheumatoid factor positivity (71% vs 20%)
- Lower anti-dsDNA and anti-Sm antibodies
- Less hypocomplementemia (C3/C4)
Prognostic Implications
Critically, SLE-SS patients have distinctive clinical manifestations and benign prognosis requiring less vigorous treatment 7. The rate of death and/or severe irreversible organ failure is significantly lower (2.4% vs 15% in SLE-only patients), with most patients remaining stable on low-dose corticosteroids.
Clinical Pitfalls and Diagnostic Challenges
Common Diagnostic Errors
The wide variety of overlapping manifestations makes differentiation difficult 9:
- Arthritis in Sjögren's can mimic rheumatoid arthritis
- Raynaud phenomenon occurs in both conditions
- Cytopenias (leukopenia, thrombocytopenia) present in both
- Cutaneous lupus features can occur in primary Sjögren's
- Antiphospholipid antibodies found in 10-20% of Sjögren's patients
Key Discriminating Features
When evaluating a patient with features of both:
Favor primary Sjögren's if:
- Predominant sicca symptoms with rapid onset in non-elderly women 1
- Positive anti-SSA/Ro without major organ involvement
- Schirmer test ≤5 mm/5 minutes
- Abnormal salivary flow rate ≤0.1 ml/minute
Favor SLE if:
- Prominent facial rash, serositis, or severe renal disease 4
- High anti-dsDNA with hypocomplementemia
- Neuropsychiatric manifestations (seizures, psychosis)
Consider overlap syndrome if:
- Both sicca symptoms AND systemic features (arthritis, serositis)
- Multiple autoantibodies (anti-SSA, anti-SSB, anti-dsDNA)
- Requires rheumatology co-management regardless 1
Management Implications
Patients with Sjögren's syndrome, whether they have secondary autoimmune disease or not, should be comanaged with a rheumatologist owing to the many possible comorbid systemic conditions 1. This is essential because both conditions can progress to life-threatening complications including vasculitis, lymphoma, and major organ failure.